Generic Name and Formulations:
Dexrazoxane 250mg, 500mg; per vial; pwd for IV infusion after reconstitution and dilution.

Company:
Pfizer Inc.
Indications for ZINECARD:
To reduce the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300mg/m2 and will continue to receive doxorubicin therapy to maintain tumor control.

Adult:
Give by slow IV push or rapid drip IV infusion. Doxorubicin should be administered within 30 minutes after starting Zinecard infusion. Administer in 10:1 ratio (eg, 500mg/m2 Zinecard: 50mg/m2 doxorubicin). Renal impairment (CrCl <40mL/min): reduce ratio to 5:1 (eg, 250mg/m2 Zinecard: 50mg/m2 doxorubicin). Hepatic impairment: may need to reduce doxorubicin dose, therefore Zinecard dose must be reduced (maintaining 10:1 ratio).

Children:
Not recommended.

Contraindications:
Chemotherapy regimens that do not contain an anthracycline.

Warnings/Precautions:
Not recommended for use with initiation of doxorubicin. Renal or hepatic impairment. Monitor cardiac function and for myelosuppression; obtain CBCs frequently. Pregnancy (Cat.D); avoid. Nursing mothers: not recommended.

Pharmacological Class:
Chelating agent.

Adverse Reactions:
Inj site pain, myelosuppression, possible secondary malignancies (see literature).

Elimination:
Renal.

Generic Availability:
YES

How Supplied:
Single-use vial—1 (w. diluent)